The accurate recognition of individuals with radiologically isolated syndrome (RIS) provides a remarkable opportunity for the early introduction of disease-modifying therapy (DMT) to extend the time to or prevent the development of an initial clinical inflammatory event, further radiological evolution, and future physical disability resulting from advancing in situ demyelination. The existing diagnostic criteria for multiple sclerosis (MS) recognize that these individuals may be identified in clinical practice, and that they are at likely risk of MS depending on the evolution of neurological symptoms and signs. 1 The general management strategy for patients with clinically isolated syndrome, relapsing remitting, and primary and secondary progressive MS involves a preventive approach aimed at reducing the probability of future disability with the hope of simultaneously preserving quality-of-life outcomes. This controversy provides a rationale to support the stance for the use of DMT in the treatment of RIS subjects.
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Central nervous system (CNS) demyelination may be best described as a "silent thief," slowly stealing proper neuronal and cellular functions and only becoming apparent when a threshold for symptom manifestation is exceeded. The management of major chronic conditions, including hypertension, diabetes mellitus, and hypercholesterolemia, entails the use of a variety of treatments within the asymptomatic phase to reduce future morbidity and mortality. The preventative approach taken is biologically plausible with designed strategies for intervention based on prior natural history outcome data. As a wealth of effective and safe treatments for MS are available, the hallmark of RIS management should mirror efforts related to these chronic conditions.
In the seminal RIS report, described subjects were identified based on the incidental appreciation of brain magnetic resonance imaging (MRI) lesions that were highly typical for MS, given their radiological appearance, frequency, and spatial distribution following a study that was performed for a reason other than for symptoms specific to MS. 2 Of 41 individuals studied, 10 (24%) were observed with contrast enhancing lesions on their baseline study. This finding placed them at higher risk for future contrast enhancing lesions on subsequent brain MRI studies (hazard ratio (HR) = 3.4, p = 0.01). As MRI relapses outnumber clinical relapses to a large degree, new imaging techniques improve the ability to identify lesions specific for MS, 3, 4 and an estimated >11,000 axons are transected per cubic centimeter of contrast enhanced tissue, 5 the early administration of DMT appears to be a sound strategy in preventing evolution of disease appreciated on MRI. The value of radiological activity early in the disease course has also been shown to be predictive of future physical wellbeing. 6 In addition, beyond the visual appreciation of lesions, other evidence supporting a decline in structural integrity includes the presence of thalamic atrophy in RIS subjects suggesting the presence of a neurodegenerative component even prior to a first clinical inflammatory demyelinating exacerbation. 7 Individuals accurately classified with RIS represent a unique group at risk of future clinical attacks related to inflammatory CNS demyelination. In the largest evaluation of RIS subjects from five countries, the 5-year risk of evolution to the first clinical attack was 34%. 8 Key risk factors included male sex, age <37 years, and the presence of demyelinating lesions within the cervical or thoracic spine. Not only were RIS subjects at risk of acute symptomatology resulting from demyelinating events but also for the development of progressive symptom evolution typical for primary progressive MS. 9 The development of each clinical attack places patients at risk of incomplete recovery in the weeks to months following the event along with future disability resulting from secondary degenerative changes, strongly supporting the rationale for treatment in this group. Treatment would also allow for a great opportunity to reduce the likelihood of future visual impairments (i.e. vision loss and double vision), bulbar difficulties, disabling neuropathic pain, permanent weakness, bladder dysfunction, and cognitive limitations.
A lack of established guidelines related to the clinical surveillance and treatment of such individuals has
Radiologically isolated syndrome should be treated with disease-modifying therapy -Yes resulted in a variety of practices with DMT recommended to some patients and not others based on clinical intuition and existing scientific data applied from established MS groups. Two large, welldesigned, multi-center, double-blinded, randomized trials in the United States and Europe are being conducted to understand the impact of two approved oral therapies in extending the time to a first clinical demyelinating event. 10, 11 The acquired data will also assist in providing guidance to healthcare providers regarding appropriate clinical and radiological surveillance recommendations.
What are our current fears regarding treatment beyond the accurate recognition of disease and subjects with RIS? Relating radiological features specific to in situ demyelination may be challenging at times. However, how truly accurate are clinical descriptions of experiences by patients that we routinely use to fulfill the clinical component of the diagnostic criteria in those with established MS? Would our concerns for treatment in RIS subjects be different if the costs of DMT were not so exorbitant or if the treatments provided were substantially safer than our current offerings? As the science related to the impact on the natural history of disease utilizing classic agents such as minocycline, 12 the potential influences of certain dietary behaviors, and improvements in general health, and supplements, including vitamin D, is advancing, our threshold levels for what we deem to be "appropriate treatment" for this unique group of individuals will continually evolve.
All healthcare providers involved in the management of MS patients practice to protect and promote wellbeing to prevent future neurological impairment. The past 25 years of scientific effort in MS has yielded a wealth of clinical trial data, highlighting the importance of early treatment along with the observation that individuals randomized to placebo or an inferior comparator fail to re-attain Expanded Disability Status Scale values to those randomized to active or superior treatment at study initiation. When properly recognized, individuals with RIS represent an at-risk group for future disability and the opportunity to intervene earlier within the disease course, even prior to a first clinical inflammatory demyelinating event, is in keeping with our goals as MS specialists-to prevent disease, early disability, and death.
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